Kun‐Huei Yeh
About
Kun‐Huei Yeh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Kun‐Huei Yeh has authored 258 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Oncology, 99 papers in Pulmonary and Respiratory Medicine and 73 papers in Surgery. Recurrent topics in Kun‐Huei Yeh's work include Colorectal Cancer Treatments and Studies (80 papers), Gastric Cancer Management and Outcomes (69 papers) and Cancer Treatment and Pharmacology (35 papers). Kun‐Huei Yeh is often cited by papers focused on Colorectal Cancer Treatments and Studies (80 papers), Gastric Cancer Management and Outcomes (69 papers) and Cancer Treatment and Pharmacology (35 papers). Kun‐Huei Yeh collaborates with scholars based in Taiwan, United States and South Korea. Kun‐Huei Yeh's co-authors include Ann‐Lii Cheng, Lyuben Tsvetkov, Hong Sun, Hui Zhang, Chih‐Hung Hsu, Shuang‐En Chuang, Li‐Tzong Chen, Pei Yen Yeh, Ying Song and Sung‐Hsin Kuo and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.
In The Last Decade
Kun‐Huei Yeh
247 papers receiving 6.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Kun‐Huei Yeh Taiwan | 38 | 3.4k | 2.3k | 2.2k | 1.4k | 1.3k | 258 | 6.7k | ||
| Young Suk Park South Korea | 41 | 4.0k 1.2× | 2.3k 1.0× | 1.3k 0.6× | 1.9k 1.4× | 738 0.6× | 227 | 6.3k | ||
| Francesco Graziano Italy | 43 | 3.3k 1.0× | 1.8k 0.8× | 1.8k 0.8× | 1.3k 0.9× | 1.3k 1.0× | 163 | 5.8k | ||
| Ferdinando De Vita Italy | 43 | 3.4k 1.0× | 2.2k 0.9× | 2.0k 0.9× | 1.2k 0.8× | 540 0.4× | 207 | 6.0k | ||
| Li‐Tzong Chen Taiwan | 41 | 2.6k 0.8× | 1.8k 0.8× | 2.4k 1.1× | 1.9k 1.3× | 1.0k 0.8× | 296 | 7.3k | ||
| Naureen Starling United Kingdom | 29 | 3.8k 1.1× | 2.7k 1.2× | 1.2k 0.5× | 1.6k 1.1× | 795 0.6× | 171 | 6.2k | ||
| Hans Prenen Belgium | 41 | 4.0k 1.2× | 2.6k 1.1× | 2.6k 1.2× | 1.3k 0.9× | 976 0.7× | 207 | 8.6k | ||
| Gennaro Galizia Italy | 43 | 2.8k 0.8× | 1.9k 0.8× | 1.2k 0.5× | 1.3k 0.9× | 731 0.6× | 140 | 5.2k | ||
| Vincenzo Catalano Italy | 40 | 3.1k 0.9× | 1.6k 0.7× | 1.4k 0.6× | 1.2k 0.8× | 900 0.7× | 124 | 5.1k | ||
| Michele Orditura Italy | 44 | 3.4k 1.0× | 2.1k 0.9× | 1.9k 0.9× | 1.2k 0.9× | 502 0.4× | 181 | 6.1k | ||
| Rossana Berardi Italy | 45 | 4.2k 1.2× | 2.8k 1.2× | 1.9k 0.9× | 1.1k 0.8× | 579 0.4× | 344 | 7.4k |
Countries citing papers authored by Kun‐Huei Yeh
Since
Specialization
Citations
This map shows the geographic impact of Kun‐Huei Yeh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kun‐Huei Yeh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kun‐Huei Yeh more than expected).
Fields of papers citing papers by Kun‐Huei Yeh
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Kun‐Huei Yeh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kun‐Huei Yeh. The network helps show where Kun‐Huei Yeh may publish in the future.
Co-authorship network of co-authors of Kun‐Huei Yeh
This figure shows the co-authorship network connecting the top 25 collaborators of Kun‐Huei Yeh. A scholar is included among the top collaborators of Kun‐Huei Yeh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kun‐Huei Yeh. Kun‐Huei Yeh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Pietrantonio, Filippo, Lisa Salvatore, Taito Esaki, et al.. (2025). Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer. Journal of Clinical Oncology. 43(19). 2147–2154.
2.
Yang, Shih‐Hung, Hsiang‐Fong Kao, Li‐Chun Lu, et al.. (2025). Improved survival with adding-on strategy after failure of nanoliposomal irinotecan plus 5-fluorouracil and leucovorin in metastatic pancreatic adenocarcinoma. Journal of the Formosan Medical Association. 125(2). 207–214.
3.
Nakamura, Yoshiaki, Keiji Hirata, Naoya Akazawa, et al.. (2024). Prognostic and predictive value of ctDNA-based MRD and actionable biomarkers in patients with resectable colorectal cancer: CIRCULATE-Japan GALAXY.. Journal of Clinical Oncology. 42(16_suppl). 3609–3609.
4.
Tsai, Hui‐Jen, Kun‐Huei Yeh, Chung‐Wu Lin, et al.. (2024). Cooperative participation of CagA and NFATc1 in the pathogenesis of antibiotics-responsive gastric MALT lymphoma. Cancer Cell International. 24(1). 383–383.
5.
Kuo, Sung‐Hsin, Kun‐Huei Yeh, Chung‐Wu Lin, et al.. (2022). Current Status of the Spectrum and Therapeutics of Helicobacter pylori-Negative Mucosa-Associated Lymphoid Tissue Lymphoma. Cancers. 14(4). 1005–1005.
6.
Chen, Kuo‐Hsing, Chia‐Lang Hsu, Yu‐Li Su, et al.. (2022). Novel prognostic implications of complement activation in the tumour microenvironment for de novo metastatic BRAF V600E mutant colorectal cancer. British Journal of Cancer. 128(1). 102–111.
7.
Chen, Kuo‐Hsing, Liang‐In Lin, Chang‐Tsu Yuan, et al.. (2021). Association between risk factors, molecular features and CpG island methylator phenotype colorectal cancer among different age groups in a Taiwanese cohort. British Journal of Cancer. 125(1). 48–54.
8.
Yeh, Kun‐Huei, Yung‐Ming Jeng, Li‐Ling Wu, et al.. (2020). Complement C1q mediates the expansion of periportal hepatic progenitor cells in senescence-associated inflammatory liver. Proceedings of the National Academy of Sciences. 117(12). 6717–6725.
9.
Ma, Weili, Kun‐Huei Yeh, Ming Yao, et al.. (2020). Comparison of clinicopathological features and treatment outcomes in aggressive primary intestinal B- and T/NK-cell lymphomas. Journal of the Formosan Medical Association. 120(1). 293–302.
10.
Yeh, Kun‐Huei, Jayesh Desai, Timothy Price, et al.. (2020). 85MO Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (BEACON CRC Study). Annals of Oncology. 31. S1276–S1276.
11.
Kuo, Sung‐Hsin, Ming‐Shiang Wu, Kun‐Huei Yeh, et al.. (2019). Novel Insights of Lymphomagenesis of Helicobacter pylori-Dependent Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Cancers. 11(4). 547–547.
12.
Yang, Shih‐Hung, Jen‐Chieh Lee, Sung‐Hsin Kuo, et al.. (2017). Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy. PLoS ONE. 12(7). e0180628–e0180628.
13.
Kuo, Sung‐Hsin, Kun‐Huei Yeh, Ming‐Shiang Wu, et al.. (2017). First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma. Scientific Reports. 7(1).
14.
Shao, Yu‐Yun, Ho‐Min Chen, Zhong‐Zhe Lin, et al.. (2015). Young patients with colorectal cancer have increased risk of second primary cancers. Japanese Journal of Clinical Oncology. 45(11). 1029–1035.
15.
Satoh, Taroh, Rui‐Hua Xu, Hyun Cheol Chung, et al.. (2014). Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study. Journal of Clinical Oncology. 32(19). 2039–2049.
16.
Kuo, Sung‐Hsin, Kun‐Huei Yeh, Ming‐Shiang Wu, et al.. (2012). Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori–positive gastric diffuse large B-cell lymphomas. Blood. 119(21). 4838–4844.
17.
Lin, Wei–Hsiang, Shiou‐Hwei Yeh, Kun‐Huei Yeh, et al.. (2012). Telomerase‐specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice. International Journal of Cancer. 132(6). 1451–1462.
18.
Kuo, Sung‐Hsin, Wen‐Hui Weng, Ping‐Ning Hsu, et al.. (2011). Establishment of a novel MALT lymphoma cell line, ma‐1, from a patient with t(14;18)(q32;q21)‐positive Helicobacter Pylori‐Independent Gastric MALT Lymphoma. Genes Chromosomes and Cancer. 50(11). 908–921.
19.
Yang, James Chih‐Hsin, Kun‐Huei Yeh, Fu‐Chang Hu, et al.. (2008). EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. Lung Cancer. 64(3). 346–351.
20.
Hsu, Chiun, et al.. (1997). MVP (mitomycin-C, vinblastine, cisplatin) salvage chemotherapy for relapsed and refractory metastatic breast cancer.. PubMed. 96(3). 185–8.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Young Suk Park Breakdown of academic impact, for papers by Francesco Graziano Breakdown of academic impact, for papers by Ferdinando De Vita Breakdown of academic impact, for papers by Li‐Tzong Chen Breakdown of academic impact, for papers by Naureen Starling Breakdown of academic impact, for papers by Hans Prenen Breakdown of academic impact, for papers by Gennaro Galizia Breakdown of academic impact, for papers by Vincenzo Catalano Breakdown of academic impact, for papers by Michele Orditura Breakdown of academic impact, for papers by Rossana Berardi